MEOX2 Participates in Hepatic Stellate Cells-Induced Liver Fibrosis by Regulating the PI3K/AKT Signaling Pathway

被引:0
|
作者
Wang, Qiong [1 ]
Li, Ting [2 ]
He, Yansha [2 ]
Rao, Chunyan [2 ]
机构
[1] Zi Yang Cent Hosp, Dept Gastroenterol, Ziyang 641300, Sichuan, Peoples R China
[2] Chongqing Tradit Chinese Med Hosp, Dept Liver Dis, Chongqing 400021, Peoples R China
关键词
liver fibrosis; hepatic stellate cells; bioinformatics analysis; MEOX2; PI3K/AKT; PHLPP; PDGF; INFLAMMATION; MECHANISMS;
D O I
10.24976/Discov.Med.202436185.110
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Hepatic stellate cells (HSCs) serve as the crucial accelerating factor in the progression of liver fibrosis (LF). In contrast to HSCs, adult-derived human liver stem/progenitor cells (ADHLSCs) exhibit greater potency in terms of differentiation and proliferation, rendering them highly applicable in LF treatment. The objective of this study is to identify new therapeutic targets for LF by comparing differentially expressed genes (DEGs) between ADHLSCs and HSCs. Methods: We investigated DEGs between ADHLSCs and HSCs using the GSE49995 dataset obtained from the Gene Expression Omnibus (GEO) database, aiming to identify new therapeutic targets for LF. Subsequently, we activated HSCs to delve deeper into the mesenchyme homeobox 2 (MEOX2), PH domain Leucine-rich repeat protein phosphatase (PHLPP), and Phosphoinositide 3kinase (PI3K)/protein kinase B (AKT) signaling pathways in LF progression, employing platelet-derived growth factor (PDGF), and conducted infection with Overexpression (OE)-MEOX2 and shRNA-MEOX2 (sh-MEOX2) lentiviruses. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay, while cell proliferation was evaluated through 5-ethynyl-2 '-deoxyuridine (EdU) staining and flow cytometry. Relative mRNA expression levels were determined via qPCR. Western blot analysis was performed to measure protein expression levels, and the regulatory role of MEOX2 was investigated using dual luciferase reporter Results: We identified 332 DEGs that were down-regulated and 201 DEGs that were up-regulated between ADHLSCs and HSCs. Notably, MEOX2 expression in ADHLSCs was significantly reduced. These DEGs primarily participated in the collagencontaining extracellular matrix and the PI3K/AKT signaling pathway. MEOX2 could inhibit cancer cell proliferation via the PI3K/AKT signaling pathway. Additionally, the JASRPAR2022 database predicted the target gene PHLPP of MEOX2. Our results indicated that OE-MEOX2 significantly inhibited HSCs' cell vitality and proliferation. Further analysis revealed that MEOX2 binds to PHLPP promoters, thereby up-regulating its transcription. This action led to the inhibition of p-AKT expression, consequently reducing HSC proliferation and slowing the progression of LF. Conclusions: MEOX2 up-regulates PHLPP expression and inhibits AKT phosphorylation, thereby reducing the cell activity and proliferation ability of HSCs and inhibiting the progression of LF.
引用
收藏
页码:1199 / 1209
页数:11
相关论文
共 50 条
  • [41] Amifostine attenuates bleomycin-induced pulmonary fibrosis in mice through inhibition of the PI3K/Akt/mTOR signaling pathway
    Yang, Wenting
    Pan, Lin
    Cheng, Yiju
    Wu, Xiao
    Huang, Songsong
    Du, Juan
    Zhu, Honglan
    Zhang, Menglin
    Zhang, Yuquan
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [42] Gynura divaricataexerts hypoglycemic effects by regulating the PI3K/AKT signaling pathway and fatty acid metabolism signaling pathway
    Xu, Wenjun
    Lu, Zhongxia
    Wang, Xin
    Cheung, Man Hei
    Lin, Meiai
    Li, Changyu
    Dong, Yu
    Liang, Chun
    Chen, Yitao
    NUTRITION & DIABETES, 2020, 10 (01)
  • [43] Hydrogen sulfide ameliorates rat myocardial fibrosis induced by thyroxine through PI3K/AKT signaling pathway
    Liu, Maojun
    Li, Zining
    Liang, Biao
    Li, Ling
    Liu, Shengquan
    Tan, Wenting
    Long, Junrong
    Tang, Fen
    Chu, Chun
    Yang, Jun
    ENDOCRINE JOURNAL, 2018, 65 (07) : 769 - 781
  • [44] Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis
    Cindy X. Cai
    Hema Buddha
    Shobha Castelino-Prabhu
    Zhiwei Zhang
    Robert S. Britton
    Bruce R. Bacon
    Brent A. Neuschwander-Tetri
    Digestive Diseases and Sciences, 2017, 62 : 968 - 978
  • [45] Study of EGCG induced apoptosis in lung cancer cells by inhibiting PI3K/Akt signaling pathway
    Gu, J-J
    Qiao, K-S
    Sun, P.
    Chen, P.
    Li, Q.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (14) : 4557 - 4563
  • [46] Lipopolysaccharides induce Smad2 phosphorylation through PI3K/Akt and MAPK cascades in HSC-T6 hepatic stellate cells
    Kao, Ying-Hsien
    Chen, Po-Han
    Wu, Tin-Ya
    Lin, Yu-Chun
    Tsai, Ming-Shian
    Lee, Po-Huang
    Tai, Tzong-Shyuan
    Chang, Huoy-Rou
    Sun, Cheuk-Kwan
    LIFE SCIENCES, 2017, 184 : 37 - 46
  • [47] Rosmanol Effectively Prevents Diethylnitrosamine-induced Hepatocellular Carcinoma in Rats by Regulating the PI3K/Akt Signaling Pathway
    Cao, Wei
    Liu, Qi
    Wang, Ying
    Chen, Lianfeng
    PHARMACOGNOSY MAGAZINE, 2024,
  • [48] Germacrone Attenuates Hepatic Stellate Cells Activation and Liver Fibrosis via Regulating Multiple Signaling Pathways
    Li, Zhiyong
    Wang, Zhilei
    Dong, Fang
    Shi, Wei
    Dai, Wenzhang
    Zhao, Jing
    Li, Qiang
    Fang, Zhi-E
    Ren, Lutong
    Liu, Tingting
    Wei, Ziying
    Mou, Wenqing
    Lin, Li
    Yang, Yan
    Xiao, Xiaohe
    Ma, Li
    Bai, Zhaofang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [49] ARRDC3 inhibits liver fibrosis and epithelial-to-mesenchymal transition via the ITGB4/PI3K/Akt signaling pathway
    Zhang, Bingling
    Wu, Feng
    Li, Pingping
    Li, Haiding
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2023, 45 (02) : 160 - 171
  • [50] PI3K/AKT signaling pathway associates with pyroptosis and inflammation in patients with endometriosis
    An, Mingli
    Fu, Xinping
    Meng, Xin
    Liu, Huimin
    Ma, Yiming
    Li, Ying
    Li, Qingxue
    Chen, Jingwei
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2024, 162